Insight on Pharmaceuticals and Healthcare in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Report
Report

Myelodysplastic Syndrome: An Underserved Population Offers Commercial Opportunity

SuperGen/MGI Pharma's Dacogen and Celgene's Revlimid are in pre-registration for treatment of myelodysplastic syndrome (MDS). However, a significant proportion of the MDS population will be left underserved by pharmacotherapy.

Published By Datamonitor
18 Oct 2005 $1900
Buy
Report
Report

Pipeline and Commercial Insight: Moderate to Severe Chronic Nociceptive Pain - Anti-abuse opioids set to prosper

Analysis of the current and future moderate to severe chronic nociceptive pain market with sales forecasts to 2019 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK) of key brands, generics, and pipeline products.

Published By Datamonitor
20 Aug 2010 $15200
Buy
Report
Report

Stakeholder Insight: Gastric Cancer

Explores key issues in the gastric cancer market, including diagnosis and treatment patterns, specific drug regimens used at each line of therapy, key prescribing influences and predicted performance of late-phase pipeline products.

Published By Datamonitor
15 Sep 2010 $15200
Buy
Report
Report

Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity

Datamonitor surveyed 183 rheumatologists in the seven major markets to gain insight into rheumatoid arthritis diagnosis, patient segmentation, current and future prescribing patterns, factors influencing decision making and key treatment challenges.

Published By Datamonitor
17 Sep 2010 $15200
Buy
Report
Report

Pipeline and Commercial Insight: Hormonal Replacement Therapy for Menopausal Symptoms - Safety fears continue to haunt the market

In-depth analysis of the current and future hormonal replacement therapy (HRT) for menopausal symptoms market across the seven major countries (US, Japan, France, Germany, Italy, Spain, UK), supported by key opinion leader comment.

Published By Datamonitor
27 Sep 2010 $15200
Buy
Report
Report

Pipeline and Commercial Insight: Testosterone Replacement Therapy - Topical formulations drive market growth

In-depth analysis of the current and future testosterone replacement therapy prescription market across the seven major markets (US, Japan, France, Germany, Italy, Spain, UK), supported by key opinion leader insight.

Published By Datamonitor
27 Sep 2010 $15200
Buy
Report
Report

Forecast Insight: Asthma/COPD - Pipeline potential outweighs downward pressure from generics

Asthma and COPD market forecast for the seven major markets, incorporating the latest data from the European Respiratory Society 2010 Congress. Recent advances and setbacks of marketed/pipeline products and generics companies' actions are covered.

Published By Datamonitor
29 Sep 2010 $15200
Buy
Report
Report

Pipeline and Commercial Insight: Pneumococcal and Meningococcal Vaccines

This report explores key issues in pneumo-and meningococcal vaccines the seven major markets. It contains an analysis of epidemiological trends, in-depth assessment of currently marketed and pipeline vaccines and a ten-year sales forecast.

Published By Datamonitor
19 Oct 2010 $6400
Buy
Report
Report

Forecast Insight: Antidiabetics - UPDATE 2: Bydureon delay boosts Victoza sales, but the status quo remains largely unchanged. Avandia sales restrictions lead to patient switching, opportunities for multiple drug classes.

Analysis of the competitive landscape and the recent changes in antidiabetics across seven major markets. Analysis of the threats to currently marketed drugs. Assessment of the opportunities available to novel agent classes.

Published By Datamonitor
22 Oct 2010 $15200
Buy
Report
Report

Infectious Diseases Vaccine Market Overview

This report provides an overview of the vaccines industry with detailed profiles of the 5 major vaccine companies. It analyzes trends, sales, R&D and licensing strategies, portfolios and pipelines as well as other individual strengths & weaknesses.

Published By Datamonitor
25 Oct 2010 $6400
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.